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Abstract: Incorporation of proteins into dextran sulfate (DS)-chitosan (CS) nanoparticles 
(DSCS NPs) is commonly performed using entrapment procedures, in which protein molecules 
are mixed with DS and CS until particle formation occurs. As DS is an analog of heparin, the 
authors examined whether proteins could be directly incorporated into preformed DSCS NPs 
through a heparin binding domain-mediated interaction. The authors formulated negatively-
charged DSCS NPs, and quantified the amount of charged DS in the outer shell of the particles. 
The authors then mixed the DSCS NPs with heparin-binding proteins (SDF-1α, VEGF, FGF-2, 
BMP-2, or lysozyme) to achieve incorporation. Data show that for DSCS NPs containing 
100 nmol charged glucose sulfate units in DS, up to ~1.5 nmol of monomeric or ~0.75 nmol 
of dimeric heparin-binding proteins were incorporated without significantly altering the size 
or zeta potential of the particles. Incorporation efficiencies of these proteins were 95%–100%. 
In contrast, serum albumin or serum globulin showed minimal incorporation (8% and 4%, 
respectively) in 50% physiological saline, despite their large adsorption in water (80% and 
92%, respectively). The NP-incorporated SDF-1α and VEGF exhibited full activity and sustained 
thermal stability. An in vivo aerosolization study showed that NP-incorporated SDF-1α persisted 
in rat lungs for 72 h (~34% remaining), while free SDF-1α was no longer detectable after 16 h. 
As many growth factors and cytokines contain heparin-binding sites/domains, incorporation 
into preformed DSCS NPs could facilitate in vivo applications of these proteins.
Keywords: polyelectrolyte complex, polysaccharide, glycan, glycosaminoglycan
Introduction
Therapeutic proteins are increasingly used in the clinical setting; their highly specific 
and uniquely complex functions are beyond the capabilities of small drug molecules.1 
However, owing to the lengthy process of production, therapeutic proteins are often 
limited in supply and high in cost. Proteins are also prone to inactivation, denaturation, 
and degradation. Improving their in vitro stability and in vivo half-life is essential for 
clinical applications.2
Compared with other nanoparticle (NP) systems, dextran sulfate (DS)-chitosan (CS) 
NPs (DSCS NPs) are particularly useful for protein delivery. DS and CS are derivatives 
of natural glycans and are completely water soluble. Formation of DSCS NPs occurs 
in water via charge-charge interactions, which pose minimal risk for denaturation or 
inactivation of the incorporated proteins. Additionally, binding to DS or CS in the 
matrix of NPs provides dynamic immobilization and protection of the incorporated 
proteins. In fact, DSCS NP-incorporated peptides/proteins have been previously shown 
to exhibit enhanced stability and/or sustained in vivo effects/retention.3–10
The current DSCS NP system, however, has some drawbacks. The most critical of 
these limitations is the instability of the NPs in physiological saline (0.15 M NaCl), 
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since the structure of particles is based on electrostatic inter-
actions. Additionally, although proteins can be incorporated 
into DSCS NPs, the efficiency of incorporation has been 
less than desirable. This limitation is related to the particle 
preparation procedure (an entrapment procedure), which 
requires that proteins are mixed with DS and CS from the 
beginning and stirred together until particle formation. Since 
only a fraction of the initial DS and CS forms particles, the 
remainder is washed away at the end of the preparation, tak-
ing along with them the bound, but unincorporated, proteins. 
In the authors previous studies, the incorporation efficiency 
of VEGF and SDF-1α was 40% and 80%, respectively.9,10 
These efficiencies are not so low compared to many other 
techniques, but are impractical for therapeutic proteins owing 
to their extreme costs.
To solve these issues, the authors sought to separate the 
processes of DSCS NP preparation and protein incorpora-
tion. Preparation of DSCS NPs without proteins would allow 
chemical modifications of the NPs to reinforce their salt 
resistance. Direct incorporation of proteins into preformed 
DSCS NPs would prevent their loss during particle synthesis. 
Nevertheless, questions remained as to whether proteins 
can be efficiently incorporated into the preformed NPs and 
whether the incorporation affects the colloidal stability of the 
particles leading to their aggregation/precipitation. 
The outer shell of negatively charged DSCS NPs 
comprises un-neutralized or charged DS, which is an analog 
of heparin.11 Proteins that contain a heparin-binding site/
domain are known to have high affinity interactions with 
heparin or heparan sulfate.12,13 The authors, therefore, hypoth-
esized that these proteins could be efficiently incorporated 
into preformed DSCS NPs. There are more than 435 heparin-
binding proteins in humans,14 including many growth factors 
and cytokines. The authors chose five such proteins for this 
study whose three-dimensional structures and/or interactions 
with heparin have been well documented. This knowledge 
helped the authors to understand the stoichiometric loading 
capacity of preformed DSCS NPs and its consequence on 
the colloidal stability of the particles.
Materials and methods
Dextran sulfate sodium salt, weight-average molecular 
weight (MW) 500 kDa, was purchased from Thermo Fisher 
Scientific. Chitosan (MW range 50–190 kDa, 75%–85% 
deacetylated) (#448869), zinc sulfate, mannitol, Azure A 
chloride (#861049), and lysozyme (from chicken egg white) 
were obtained from Sigma-Aldrich. Cibacron brilliant red 
3B-A (#sc-214719) was purchased from Santa Cruz Bio-
technology. UltraPure DNase/RNase-free distilled water was 
obtained from Thermo Fisher Scientific. Recombinant human 
SDF-1α and VEGF
165
 were prepared in the authors labora-
tory as previously described.9,10 Recombinant human FGF-2 
and BMP-2 were purchased from PeproTech. Bovine serum 
albumin (BSA) was purchased from EMD Millipore. Goat 
gamma globulin was obtained from Jackson ImmunoRe-
search Laboratories. SDF-1α enzyme-linked immunosorbent 
assay (ELISA) kit (Human CXCL12/SDF-1α DuoSet) was 
purchased from R&D Systems.
Preparation of Dscs NPs
DSCS NPs were prepared in a total volume of 1.2–300 mL in 
this study. For a 300 mL preparation, 150 mL DS (1 mg/mL 
in H
2
O) was stirred at 700 rpm and mixed with 37.5 mL CS 
(1 mg/mL) for 15 min. CS was prepared by dissolving in 0.2% 
acetic acid/H
2
O, filtering through 0.8, 0.45, and 0.2 µm SFCA 
membranes consecutively, and adjusting the pH to 5.3 with 
2N NaOH. The stirring speed was then increased to 800 rpm, 
and 5.8 mL 200 mM ZnSO
4
 was added at 1 mL/min through 
a syringe pump. The mixture was stirred for another 60 min 
before the addition of 100 mL 15% mannitol. The DSCS NPs 
were precipitated by centrifugation at 20,000× g for 20 min. 
The particle pellets were washed twice with 70 mL water 
and centrifuged at 30,000× g for 40 min. The final particles 
were suspended in 12 mL 5% mannitol, divided into 0.5 mL 
aliquots, frozen at -80°C, and lyophilized for 3 days. The 
dried particles were stored desiccated at 4°C until use.
Particle size and zeta potential analysis
A DelsaNano C Particle Analyzer (Beckman) was used 
for the particle analysis following procedures described 
previously.15 Briefly, 10–15 µL particle samples were diluted 
in 0.5 or 2.5 mL water for size or zeta potential measurement, 
respectively. Standard operating procedures of the instrument 
were followed. Autocorrelation functions were analyzed by 
the Contin algorithm, and particle diameters were presented 
as cumulants. Zeta potentials were calculated from electro-
phoretic mobility using Smoluchowski approximation.
azure a assay
Azure A was dissolved in water at 1 mg/mL as a stock 
solution (stored at 4°C), and diluted to 0.02 mg/mL in water 
as a working solution. For spectrophotometric analysis, 
2 mL Azure A working solution was added to a polystyrene 
cuvette and mixed with 20 µL DS solution. Measurements 
were made within 15 min of mixing. To determine DS 
concentration in a 96-well plate, 10 µL DS standards (made 
with DS sodium salt) or NP samples (in the form of NP 
dispersion, diluted with water) in a concentration range of 
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0–0.20 mg/mL were added to plate wells. Azure A working 
solution (200 µL) was added next, followed by mixing on 
a plate shaker for 2 min. Absorbance was read at 620 nm. 
Samples were run in triplicate, and empty wells were used 
as the instrument blank.
Incorporation of proteins into Dscs NPs
Prior to protein incorporation, aliquots of lyophilized 
DSCS NPs were reconstituted with water and centrifuged at 
20,000× g for 15 min to remove ultrafine particles. Pellets 
were resuspended in 2.5% mannitol, and an Azure A assay 
was performed to determine the amount of charged DS 
in the NPs. (Ultrafine particles could have contributed to 
10%–15% of charged DS in the lyophilized particles. Thus, 
it was necessary to confirm the charged DS content with the 
Azure A assay after centrifugation.) Incorporation reactions 
were carried out by diluting specified amounts of DSCS NP 
and protein in water, 50% phosphate-buffered saline (PBS), 
or otherwise noted buffer solutions, and adding protein solu-
tion slowly to NPs while stirring at 800 rpm. Total reaction 
volume was 0.3 mL or in some cases 0.15 mL which were 
placed in a 2 mL glass vial with a 1.5×8 mm2 stir bar, or 
a 1.5 mL tube with a 3×3 mm2 stir bar, respectively. The 
mixture was stirred at 300 rpm for another 20 min. After the 
incorporation reactions, NPs were separated from unincor-
porated protein by centrifugation at 21,000× g for 20 min. 
Supernatants were collected and pellets were resuspended in 
2.5% mannitol to their original volume. Equal volumes of 
supernatants and pellets were loaded on a 4%–20% sodium 
dodecyl sulfate (SDS) gel for electrophoresis. Gels were 
stained with Coomassie blue, and protein bands were quanti-
fied by densitometric analysis as previously described using 
BioRad ImageLab software.15
Migration assay
A cell migration assay was carried out to measure the 
chemotactic activity of SDF-1α using Costar polycarbon-
ate Transwell inserts (pore size 5 µm, diameter 6.5 mm, 
Costar # 3421). SDF-1α was diluted in 0.6 mL of migration 
medium [RPMI-1640 medium containing 0.5% BSA (Sigma 
# A9576)] and added to wells in a 24-well plate (“bottom 
wells”). Transwell inserts (“top wells”) were placed into the 
bottom wells and loaded with 5×105 Jurkat cells suspended 
in 100 µL migration medium. After 2 h incubation at 37°C, 
cells that transmigrated into the bottom well were mixed 
and counted with a BD Accuri C6 flow cytometer (BD 
Biosciences). Each sample was counted twice at a preset flow 
rate (14 µL/min for 10 µL). For negative controls, the cells 
were added to the top wells with no SDF-1α in the bottom 
wells. For the input cell number, cells were added directly 
to the bottom well and counted. Migration was calculated 
as a percentage of the input cell number after subtraction of 
the numbers in negative controls.
endothelial cell proliferation assay
This assay was used to determine the activity of VEGF, for 
which a previously described procedure was followed.9 Human 
pulmonary artery endothelial cells (originally purchased from 
Lonza) were used for the assay, and a Cell Proliferation Assay 
kit, CellTiter 96, was used for estimation of cell proliferation.
Intratracheal aerosolization and analysis 
of lung tissue for sDF-1α content
Male Sprague Dawley rats weighing 200–225 g were 
purchased from Charles River Laboratories, and were 
acclimated for 4 days in the authors animal facility. Animal 
studies were performed according to protocols approved 
by the Harvard Medical Area Standing Committee on 
Animals.
Intratracheal aerosolization of SDF-1α or SDFNPs as well 
as the analysis of SDF-1α content in the lung was performed 
according to a previously described procedure.10 Briefly, 
SDF-1α or SDFNPs containing 12 µg SDF-1α were diluted 
in 50% PBS to a volume of 0.25 mL and aerosolized into rat 
lungs with a MicroSprayer Aerosolizer from Penn-Century. 
At 0, 16, 48, and 72 h after aerosolization, rat lung tissue 
was harvested and frozen in liquid nitrogen. The tissue was 
homogenized, and the total protein concentration in the homo-
genate supernatants was determined by the bicinchoninic 
acid (BCA) protein assay. Supernatant SDF-1α concentra-
tions were determined by ELISA using reagents from R&D 
systems following the manufacturer’s instructions.
Results and discussion
Preparation of Dscs NPs
For the purpose of protein incorporation, DSCS NPs were 
prepared in large batches, lyophilized in small aliquots, 
stored as dry powder, and reconstituted prior to protein 
incorporation (for details, see “Materials and methods”). 
A number of formulations were examined in order to obtain 
small, negatively charged, and stable colloidal DSCS NPs. 
The concentrations of DS and CS solutions were found to 
be optimal when each of them were prepared at 1 mg/mL 
and mixed at a volume ratio of 4:1 (DS:CS). Zinc sulfate 
and mannitol were found to be necessary for the colloidal 
stability of the particles undergoing lyophilization. The con-
centration requirements for these two reagents are described 
in the subsequent paragraphs.
International Journal of Nanomedicine 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6152
Zaman et al
The effect of mannitol on the stability of DSCS NPs 
during lyophilization is shown in Figure 1. In the absence 
of mannitol, DSCS NPs became heavily aggregated after 
lyophilization. In the presence of 0.3%–5% mannitol, both 
the size and polydispersity index of the particles were 
gradually decreased. The concentration effect plateaued at 
2.5%–5%, and 5% mannitol was chosen for the following 
DSCS NP preparation. 
The effect of zinc concentration on particle size is shown 
in Figure 2. Increasing zinc concentration from 0 to 20 mM 
led to a particle size decrease prior to lyophilization but 
increase after lyophilization. In both cases, however, the 
polydispersity indices of the particles were decreased with 
increasing zinc concentrations. A zinc sulfate concentration of 
6 mM was chosen for the following DSCS NP preparation.
Lyophilization reduced the overall size of the particles; 
however, the polydispersity indices of the particles were 
increased (Figure 2). The latter reflected an increase in hetero-
geneity of the particles, likely resulting from the generation of 
ultrafine particles during the lyophilization process. To sepa-
rate this portion from the rest of the particles, centrifugation 
(21,000× g for 20 min) was carried out after reconstitution 
of lyophilized DSCS NPs and the resulting supernatant was 
discarded. The parameters of the finally formulated particles 
are shown in Table 1.
Quantification of un-neutralized DS in 
Dscs NPs
To determine the amount of charged DS in DSCS NPs, an 
Azure A metachromatic assay was used. This assay has been 
previously established to measure concentrations of DS16 and 
heparin17 in solutions. Azure A interacts with charged and 
clustered sulfate groups in polymers (polysulfate group), but 
not neutralized or individual sulfate ions. The absorption 
spectra of Azure A after interacting with DS solutions are 
shown in Figure 3A. For the measurement of charged DS in 
DSCS NPs, absorbance at 620 nm was used and the assay 
was carried out in a 96-well plate. A typical standard curve is 
Figure 1 effect of mannitol on the stability of Dscs NPs during lyophilization. Dscs NPs were suspended in mannitol solutions at the indicated concentrations and 
lyophilized. Prior to size measurement the particles were reconstituted with water to their original volume. Data represent the mean ± sD of measurements of three 
separate preparations.
Abbreviations: aNOVa, analysis of variance; Dscs NPs, dextran sulfate-chitosan nanoparticles; sD, standard deviation.
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shown in Figure 3B, using standards made with DS sodium 
salt at concentrations from 0.04 to 0.2 mg/mL.
To confirm that Azure A assay detects charged DS 
within DSCS NPs, the assay was carried out to measure DS 
concentration from each step of particle preparation using 
aliquots taken from the preparation mixture (in the form of 
colloidal dispersion). The results are shown in Table 2. The 
Azure A-detected amount of DS decreased by ~20% after 
addition of CS to DS in the first step of NP preparation. This 
reduction was correlated to the neutralization of DS sulfate 
groups by CS, which can be calculated as follows: the molar 
mass of a glucose sulfate unit in DS (sulfur content 17%) 
is ~397 g/mol assuming a glucose unit (molar mass =180 
g/mol) with 2.3 sodium sulfate substitutions ([23+97–18] 
× 2.3=235) and one glycosidic bond (ignoring 5% branch-
ing) (-18); and the molar mass of a glucosamine unit in CS 
(80% deacetylated) is 169 g/mol, assuming 0.8 glucosamine 
unit (179 × 0.8=143), 0.2 N-acetylglucosamine unit (221 × 
0.2=44), and one glycosidic bond (-18). At the weight ratio 
of DS to CS of 4:1, the ratio of saccharide units in DS and 
CS is 1:0.59. Each unit has on average 2.3 negative charges 
in DS and 0.8 positive charges in CS. Thus, the total charge 
ratio between DS and CS is ~2.3:0.47 (5:1). When neutral-
ized, charged DS would comprise ~80% of total. This change 
remained after zinc sulfate and mannitol addition, indicating 
that the particle structure itself did not affect the detectability 
of its charged DS by Azure A. The Cibacron brilliant red 3B-A 
colorimetric assay,18,19 which measures charged CS, was also 
performed on the aliquots. (Note that the pH of CS solution 
and DS-CS mixture was 5.3 and 5.5, respectively, at which 
pH CS should be protonated as the pK
a
 of CS is ~6.5). No CS 
was detected by the assay after mixing CS with DS in particle 
preparation, indicating complete neutralization of CS. 
Table 2 also shows that the total yield of the DSCS NPs 
from this preparation is low: only 4.4% of the original amount 
of charged DS was found in the final DSCS NP preparation. 
A large amount of DS was detected in the supernatant 
fraction of the first centrifugation, which was discarded after 
separation from the particles.
Incorporation of heparin-binding proteins 
into preformed Dscs NPs
Heparin-binding proteins are defined by their high affinity 
for heparin, which is commonly demonstrated by binding the 
proteins to heparin-Sepharose resin in $0.15 M NaCl. Many 
proteins, especially those mediating intercellular signaling, 
fall into this category.14 The biological ligands of most of 
these proteins are heparan sulfate or sulfated glycosamino-
glycans, which are present on the cell surface and in the 
extracellular matrix. A heparin-binding site or domain in the 
primary or tertiary structure of the proteins is responsible for 
heparin binding, which often includes a cluster of positively 
charged amino acid residues (Lys, Arg, and His) that bind 
to heparin through electrostatic interaction.12,13 As DS is 
an analog of heparin,11 heparin-binding proteins will likely 
bind to negatively charged DSCS NPs. Nevertheless, exces-
sive binding could cause NP aggregation owing to charge 
neutralization.
Table 1 size and charge properties of large-scale nanoparticle 
preparation
Nanoparticle
preparation phase
Diameter
(nm)
Polydispersity
index
Zeta potential
(mV)
Pre-lyophilization 455±14 0.11±0.2 -45.9±5.4
Post-lyophilization 349±15 0.14±0.04 -40.0±2.6
Post-centrifugation 377±10 0.11±0.01 -43.1±1.5
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Figure 3 absorbance of azure a after interactions with Ds. 
Notes: (A) absorption spectra of azure a. Dotted lines mark the wavelengths at which absorbance proportionally changed (510 and 620 nm) or did not change (548 nm, 
isosbestic point) with increasing Ds concentration. (B) an example of a standard curve used for measuring charged Ds in a 96-well plate format.
Abbreviation: Ds, dextran sulfate.
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The authors first examined incorporation of SDF-1α 
into DSCS NPs. SDF-1α is a chemokine and an important 
stem cell homing factor.20–22 It has a distinct heparin-binding 
site,23,24 exists mainly as a monomer in solution, but forms a 
dimer upon binding to heparin.24,25 The incorporation reac-
tion was carried out by mixing SDF-1α with DSCS NPs 
at various ratios, followed by a centrifugation to separate 
unincorporated SDF-1α from DSCS NPs. The amount of 
SDF-1α in pellet and supernatant fractions was analyzed on 
SDS gels. Figure 4A shows that for reactions carried out in 
water (pH 6), the particle size and zeta potential were not sig-
nificantly altered at SDF-1α ratios between 1.3 and1.9 nmol 
per 100 nmol charged glucose sulfate units in DSCS NPs. 
Beyond this point, the particles were markedly aggregated. 
Alkaline pH (pH 8) allowed some more SDF-1α loading 
(up to 2.5 nmol per 100 nmol charged glucose sulfate units 
in DSCS NPs) before inducing aggregation. SDF-1α binding 
(as a dimer) has been known to occupy 12–14 saccharide 
units in heparin.24 The aforementioned loading limit of DSCS 
NP (in average ~1.5 nmol SDF-1α/100 nmol charged glucose 
sulfate units in DSCS NP) suggests that less than 10% of total 
charged DS can be occupied before affecting NP stability. 
Incorporation efficiency was 92%–100% at all SDF-1α load-
ing amounts tested (1–3 nmol/100 nmol charged saccharide 
units) (Figure 4B), which was greater than that obtained 
previously using an entrapment method (66%–80%).10
Incorporation of VEGF to DSCS NPs was next examined. 
VEGF is an important growth factor involved in angiogen-
esis and vasculogenesis.26 It is a disulfide-linked homodimer 
containing two heparin-binding domains located at the 
carboxyl-terminus of each monomer,27 and together they 
occupy 14 saccharide units upon heparin binding.28,29 The 
result of VEGF incorporation is shown in Figure 5. The 
maximal loading of VEGF without significantly affecting 
the size and zeta potential of the particles was 0.63–1 nmol 
Table 2 amount of azure a-detectable dextran sulfate (Ds) at 
various steps during the preparation of Dscs NP*
Preparation
steps
Volume 
(mL)
DS conc
(mg/mL)
Total DS 
(mg)
% input DS
Initial Ds 150 0.99 148.5 99.0
Post-cs addition 187.5 0.64 120 80.0
Post-ZnsO4 add 193.3 0.63 121.8 81.2
Post-mannitol add 293.3 0.41 120.3 80.2
First spin pel susp 72 0.16 11.5 7.7
second spin pel susp 72 0.12 8.6 5.7
Final pel susp 12 0.55 6.6 4.4
Notes: *Preparation of Dscs NPs was initiated with 150 ml Ds at 1 mg/ml. after 
each preparation step, 0.1 ml aliquot was removed and diluted in water for azure a 
measurement. Data represent the mean from four separate preparations.
Abbreviations: Dscs NP, dextran sulfate-chitosan nanoparticle; add, addition; pel 
susp, pellet suspension; conc, concentration.
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Figure 4 Incorporation of sDF-1α into preformed Dscs NPs. sDF-1α and Dscs NPs were mixed at the indicated ratios, which are expressed as µg of sDF-1α per 40 µg 
charged Ds, or nmol of sDF-1α per 100 nmol charged glucose sulfate units (gluc-sO3-) in Dscs NPs. 
Notes: (A) shows particle sizes and zeta pontentials of the resulting sDF-1α-incorporated particles. (B) shows sDs gel analysis of sDF-1α distribution in centrifugal pellet 
(P) and supernatant (s) of the incorporation samples. graphs represent mean ± sD from three separate preparations. *P0.05 compared to no sDF-1α control.
Abbreviations: Dscs NPs, dextran sulfate-chitosan nanoparticles; sDs, sodium dodecyl sulfate; sD, standard deviation; sDFNP, NP-incorporated sDF-1α.
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VEGF per 100 nmol charged glucose sulfate units in DSCS 
NPs (Figure 5A). Similar to that found with SDF-1α, 
the loading limit of VEGF suggested that less than 10% 
charged glucose sulfate units in DSCS NPs can be occupied 
without affecting the stability of the NPs. The incorpora-
tion efficiency was 96%–100% at all tested VEGF loading 
amounts (0.25–2 nmol/100 nmol charged saccharide units) 
(Figure 5B), which is greater than that achieved by an 
entrapment method, which were ~40% or 50%–80% from 
two separate studies.5,9
Albumin and globulins are the most abundant proteins in 
blood. As proteins can adsorb to the surfaces of various inor-
ganic/organic materials, the authors examined the adsorption 
of these proteins to preformed DSCS NPs. In this study, 50 µg 
of BSA (0.75 nmol) or goat gamma globulin (0.42 nmol) 
were mixed with DSCS NPs (containing 100 nmol charged 
glucose sulfate units) in water or 50% PBS. As shown in 
Figure 6, significant amounts of BSA and gamma globulin 
were adsorbed to DSCS NPs when mixed in water (80% and 
92%, respectively), while only 8% and 4% adsorbed, respec-
tively, when mixed in 50% PBS. In contrast, incorporations of 
SDF-1α and VEGF to DSCS NPs were not affected by 50% 
PBS (Figure 6). Owing to the instability of DSCS NPs in salt 
solutions, 100% PBS could not be used in this test. 
Incorporation of other heparin-binding proteins was 
briefly studied to confirm their loading ratios to DSCS NPs. 
Human FGF-2 is a monomeric protein that forms a dimer 
upon binding to heparin.30–32 Human BMP-2, by contrast, is 
a disulfide-linked homodimeric heparin-binding protein.33,34 
Egg white lysozyme is a monomeric heparin-binding 
protein,35,36 which is also present in human milk. Purified 
lysozyme could be obtained from commercial sources in 
$
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Figure 5 Incorporation of VegF into preformed Dscs NPs. VegF and Dscs NPs were mixed at the indicated ratios, which were achieved by increasing the amount of VegF 
and keeping the fixed amount of DSCS NPs at lower ratios (10–25 µg VegF/40 µg Ds), or vice versa at higher VegF/NP ratios (20–80 µg/40 µg Ds). 
Notes: (A) shows particle sizes and zeta potentials of resulting VegF-incorporated particles. (B) shows sDs gel analysis of VegF distribution in centrifugal pellet (P) and 
supernatant (s) of the incorporation samples. Data represent the mean ± sD from three separate preparations. *P0.05 compared to no VegF control.
Abbreviations: Dscs NPs, dextran sulfate-chitosan nanoparticles; sDs, sodium dodecyl sulfate; VegF NP, NP-incorporated VegF; MW, molecular weight; sD, standard 
deviation.
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relatively large quantity and low cost. Incorporation of each 
protein was examined at two different loading ratios. For 
FGF-2 and lysozyme, the ratios were 1 or 2 nmol protein 
per 100 nmol charged glucose sulfate units in DSCS NPs; 
for BMP-2, the ratios were reduced to half, as BMP-2 is a 
dimer. As shown in Table 3, incorporation efficiencies of 
these proteins in 50% PBS were between 95% and 100%. 
Size and zeta potential of DSCS NPs were not significantly 
changed except for that of FGF-2-incorporated DSCS NPs 
at a protein-to-charged glucose sulfate unit ratio 2:100. 
Together with the findings from SDF-1α and VEGF incor-
poration, the maximum loading of heparin-binding proteins 
to DSCS NPs was ~1.5 nmol for monomeric proteins or 
0.75 nmol for dimeric proteins per 100 nmol charged glucose 
sulfate units in DSCS NP.
activity and stability of NP-incorporated 
sDF-1α (sDFNP) and VegF
To examine the chemotactic activity of SDFNP, a Jurkat cell 
migration assay was carried out. Free SDF-1α and SDFNP 
were diluted to 1 or 3 ng/mL for measurements. As shown in 
Figure 7A, at both SDF-1α concentrations analyzed, SDFNP 
exhibited similar or slightly greater migration activities com-
pared to those of SDF-1α, indicating that the NP incorpora-
tion did not block the chemotactic activity of SDF-1α. The 
slightly greater activity of SDFNP at 1 ng/mL was perhaps 
a consequence of a protective effect of NP binding as the 
protein was extremely diluted. This phenomenon was also 
observed with the VEGF activity assay at the 1 ng/mL dose. 
It should be noted that the chemotactic activity exerted by 
SDFNP was from NP-bound SDF-1α rather than the free 
(released) protein. The authors have previously reported that 
only 3% of SDF-1α was released from SDFNP after 7 days 
of incubation at 37°C in 50% PBS,10 which was confirmed 
in this study (data not shown). The NP-bound SDF-1α was 
able to compete with free form of SDF-1α in the migration 
assay, and bind to its receptor (CXCR4) on Jurkat cells in 
the NP form.10
To determine thermal stability, SDF-1α and SDFNP 
were diluted in 2.5% mannitol and incubated at 37°C for up 
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Figure 6 Comparison of incorporation efficiencies of SDF-1α, VegF, Bsa, and gamma globulin in h2O or 5% PBs. Incorporations were carried out by mixing indicated 
proteins with Dscs NPs in water (h2O) or 50% PBs for 20 min. Protein distributions in centrifugal pellet (P) and supernatant (s) of the incorporation samples were analyzed 
on sDs gels. 
Notes: (A and B) show representative sDs gel images, and (C) shows the protein distributions based on densitometry analysis of the bands. Data represent the mean ± sD 
from three to four separate incorporation reactions.
Abbreviations: PBs, phosphate-buffered saline; Dscs NPs, dextran sulfate-chitosan nanoparticles; sDs, sodium dodecyl sulfate; sD, standard deviation; ctl, control.
Table 3 Incorporation of FgF-2, BMP-2, and lysozyme into preformed Dscs NPs*
Protein
 
Protein: Gluc-SO3
-
(nmol:nmol)
Incorp efficiency
(%)
Diameter
(nm)
Polydisp index
 
Zeta potential
(mV)
None 336±4 0.08±0.01 -40.6±1.6
FgF-2 1:100 95±1 356±11 0.10±0.03 -41.9±3.1
FgF-2 2:100 96±1 437±75 0.22±0.06 -43.3±2.9
BMP-2 0.5:100 100 380±6 0.11±0.02 -42.6±3.2
BMP-2 1:100 100 389±11 0.09±0.03 -41.7±0.2
lysozyme 1:100 100 357±1 0.09±0.01 -43.5±3.5
lysozyme 2:100 100 353±5 0.09±0.02 -44.4±3.8
Note: *Incorporation reactions were carried out by mixing indicated ratios of protein and charged glucose sulfate in Dscs NP in 50% PBs for 20 min.
Abbreviations: Dscs NPs, dextran sulfate-chitosan nanoparticles; PBs, phosphate-buffered saline; Incorp, incorporation; Polydisp, polydispersity. 
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to 24 days. Aliquots were removed at various time points 
and analyzed with migration assays. As shown in Figure 7B, 
after 6,14, and 24 days incubation at 37°C, SDF-1α activity 
was 61%±9%, 29%±12%, and 29%±5%, respectively, while 
those of SDFNP were 96%±5%, 80%±20%, and 52%±4%, 
respectively. Thus, SDF-1α thermal stability was improved 
by incorporation into DSCS NPs. No previous report has 
examined the thermal stability of SDF-1α; however, studies 
have shown that binding to heparin protects SDF-1α from 
protease degradation.37,38
VEGF activity was examined by an endothelial cell pro-
liferation assay. As shown in Figure 8A, NP-incorporated 
VEGF (VEGF NP) had similar activity to VEGF, which was 
consistent with a previous finding using VEGF NP made by 
an entrapment method.9 To compare thermal stability between 
VEGF and VEGF NPs, samples were incubated at 37°C for 
up to 20 days. The activities of the samples were analyzed 
at several incubation times, and compared with a VEGF 
stock (control) kept at 4°C. The activities of the samples at 
day 13 and day 20 incubations are shown in Figure 8B and C. 
Results show that both VEGF and VEGF NP retained full 
activity after incubation at 37°C for 20 days, indicating that 
the free form of VEGF is unusually thermally stable and 
the 20-day incubation at 37°C did not differ in the stability 
between VEGF and VEGF NP. This result is consistent with 
previous studies using a differential scanning calorimetry 
method to determine the thermal stability of VEGF.5,39 The 
studies found that VEGF has an unusually high melting tem-
perature of 107°C or 108°C,5,39 indicating a very high thermal 
stability. VEGF NP further increases the melting temperature 
to over 115°C,5 indicating that the thermal stability of VEGF 
was further enhanced by incorporation into DSCS NPs.
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Figure 7 comparison of activity and thermal stability of sDF-1α in free (sDF-1α) and NP-incorporated (sDFNP) forms. 
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*P0.05 compared to activity of free sDF-1α.
Abbreviations: sDFNP, nanoparticle-incorporated sDF-1α; sD, standard deviation.
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Figure 8 comparison of activity and thermal stability of VegF in free and NP-incorporated (VegF NP) forms. 
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In vivo retention time of sDFNP
To determine the in vivo retention time, SDF-1α or SDFNP 
were aerosolized into rat lungs. Lung tissue was harvested 
at various periods of time after delivery, and examined 
for SDF-1α content by ELISA. As shown in Figure 9, 
SDF-1α content in the lung tissue given the free form of 
SDF-1α was nearly undetectable 16 h after aerosolization 
(~2% remaining), but remained detectable in the lungs which 
received SDFNP at 100%, 76%, and 34% of initial values at 
16 h, 48 h, and 72 h after delivery, respectively. This retention 
time pattern was similar to the SDFNPs made previously by 
the entrapment method.10
advantage of the current system over 
entrapment and adsorption techniques
In the current system, DSCS NPs are prepared in large batches, 
stored in small aliquots, and quantified by the Azure A assay 
to determine the final content of charged DS in the NPs. 
These steps allow the incorporation of the heparin-binding 
protein to be extremely convenient (a 20 min mixing), highly 
efficient (95%–100%), and quantitative (the whole mixture 
can be delivered directly). These advantages are unparalleled 
by preparations produced by entrapment procedures, which 
required a 20–24 h processing period owing to the de novo 
synthesis of particles and partial (limited) incorporation of 
input proteins (40%–80%). The final amount of protein in the 
resulting NPs needed to be quantified individually by an SDS 
gel analysis. Nonspecific adsorptions of proteins to various 
bio-macromolecules (proteins, nucleotides, polysaccharides, 
and lipid vesicles) are commonly observed in aqueous solu-
tions without salt. These adsorptions are often disrupted by 
salt solutions at physiological ionic strength (equivalent to 
0.15 M NaCl or saline). Therefore, BSA or gamma globulin 
had minimal adsorption (4%–8%) to DSCS NPs in the pres-
ence of 50% PBS.
Conclusion
In order to incorporate therapeutic proteins into DSCS NPs 
efficiently, this study examined specific binding-mediated 
particle incorporation. Heparin-binding proteins were chosen 
for the incorporation as DS in the outer shell of DSCS NPs 
is an analog of heparin. A heparin-binding site could also be 
tagged to a protein during recombinant production to allow 
the specific binding. An Azure A assay was established to 
quantify charged DS in the particles; corresponding glucose 
sulfate units in the DS were calculated to estimate the loading 
capacity of DSCS NPs. Data show that incorporation efficien-
cies of heparin-binding proteins (SDF-1α, VEGF, FGF-2, 
BMP-2, or lysozyme) to preformed DSCS NPs were between 
95% and 100%. The size and zeta potential of the NPs were 
not significantly affected at protein loading conditions up 
to ~1.5 nmol of monomeric or ~0.75 nmol of dimeric heparin-
binding proteins per 100 nmol charged glucose sulfate units 
in DSCS NPs. In comparison, nonspecific adsorption of BSA 
or gamma globulin to DSCS NPs showed minimal incorpora-
tion in 50% PBS (8% and 4%, respectively) but a substantial 
incorporation in water (80% and 92%, respectively). Incorpo-
ration into DSCS NPs did not interfere with the activities of 
SDF-1α and VEGF, and enabled greater thermal stability of 
the proteins. It also markedly extended the in vivo retention 
time of SDF-1α compared to its free form. These data show 
that heparin binding domain-mediated specific interaction 
allows an efficient incorporation of proteins into preformed 
DSCS NPs. This incorporation provides enhanced in vitro 
and in vivo stability of the proteins, which could be useful 
for their various biological applications.
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